262 related articles for article (PubMed ID: 16352597)
1. Crystal structure of human cytochrome P450 2D6.
Rowland P; Blaney FE; Smyth MG; Jones JJ; Leydon VR; Oxbrow AK; Lewis CJ; Tennant MG; Modi S; Eggleston DS; Chenery RJ; Bridges AM
J Biol Chem; 2006 Mar; 281(11):7614-22. PubMed ID: 16352597
[TBL] [Abstract][Full Text] [Related]
2. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6.
Kirton SB; Kemp CA; Tomkinson NP; St-Gallay S; Sutcliffe MJ
Proteins; 2002 Nov; 49(2):216-31. PubMed ID: 12211002
[TBL] [Abstract][Full Text] [Related]
3. A refined substrate model for human cytochrome P450 2D6.
de Groot MJ; Bijloo GJ; Martens BJ; van Acker FA; Vermeulen NP
Chem Res Toxicol; 1997 Jan; 10(1):41-8. PubMed ID: 9074801
[TBL] [Abstract][Full Text] [Related]
4. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
[TBL] [Abstract][Full Text] [Related]
5. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6.
Paine MJ; McLaughlin LA; Flanagan JU; Kemp CA; Sutcliffe MJ; Roberts GC; Wolf CR
J Biol Chem; 2003 Feb; 278(6):4021-7. PubMed ID: 12446689
[TBL] [Abstract][Full Text] [Related]
6. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
7. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding.
McLaughlin LA; Paine MJ; Kemp CA; Maréchal JD; Flanagan JU; Ward CJ; Sutcliffe MJ; Roberts GC; Wolf CR
J Biol Chem; 2005 Nov; 280(46):38617-24. PubMed ID: 16162505
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of human cytochrome P450 2D6 with prinomastat bound.
Wang A; Savas U; Hsu MH; Stout CD; Johnson EF
J Biol Chem; 2012 Mar; 287(14):10834-43. PubMed ID: 22308038
[TBL] [Abstract][Full Text] [Related]
9. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding.
Modi S; Paine MJ; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
Biochemistry; 1996 Apr; 35(14):4540-50. PubMed ID: 8605204
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6.
de Graaf C; Oostenbrink C; Keizers PH; van Vugt-Lussenburg BM; van Waterschoot RA; Tschirret-Guth RA; Commandeur JN; Vermeulen NP
Curr Drug Metab; 2007 Jan; 8(1):59-77. PubMed ID: 17266524
[TBL] [Abstract][Full Text] [Related]
11. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.
Guengerich FP; Miller GP; Hanna IH; Martin MV; Léger S; Black C; Chauret N; Silva JM; Trimble LA; Yergey JA; Nicoll-Griffith DA
Biochemistry; 2002 Sep; 41(36):11025-34. PubMed ID: 12206675
[TBL] [Abstract][Full Text] [Related]
12. Analysis of CYP2D6 substrate interactions by computational methods.
Ito Y; Kondo H; Goldfarb PS; Lewis DF
J Mol Graph Model; 2008 Feb; 26(6):947-56. PubMed ID: 17764997
[TBL] [Abstract][Full Text] [Related]
13. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.
Guengerich FP; Hanna IH; Martin MV; Gillam EM
Biochemistry; 2003 Feb; 42(5):1245-53. PubMed ID: 12564927
[TBL] [Abstract][Full Text] [Related]
14. Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.
Hanna IH; Kim MS; Guengerich FP
Arch Biochem Biophys; 2001 Sep; 393(2):255-61. PubMed ID: 11556812
[TBL] [Abstract][Full Text] [Related]
15. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building.
Koymans LM; Vermeulen NP; Baarslag A; Donné-Op den Kelder GM
J Comput Aided Mol Des; 1993 Jun; 7(3):281-9. PubMed ID: 8377025
[TBL] [Abstract][Full Text] [Related]
16. Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.
Unwalla RJ; Cross JB; Salaniwal S; Shilling AD; Leung L; Kao J; Humblet C
J Comput Aided Mol Des; 2010 Mar; 24(3):237-56. PubMed ID: 20361239
[TBL] [Abstract][Full Text] [Related]
17. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
[TBL] [Abstract][Full Text] [Related]
18. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
[TBL] [Abstract][Full Text] [Related]
19. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.
Wang A; Stout CD; Zhang Q; Johnson EF
J Biol Chem; 2015 Feb; 290(8):5092-5104. PubMed ID: 25555909
[TBL] [Abstract][Full Text] [Related]
20. The role of the length and sequence of the linker domain of cytochrome b5 in stimulating cytochrome P450 2B4 catalysis.
Clarke TA; Im SC; Bidwai A; Waskell L
J Biol Chem; 2004 Aug; 279(35):36809-18. PubMed ID: 15194706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]